AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23283923 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol lozenges (5 lozenges of 1.0 gram daily for 33 months)
Number of subjects: 691
Study 23283923 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges (5 lozenges daily for 33 months)
Number of subjects: 691
Study 20868639 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended dosing (every second day)
Number of subjects: 35
Study 20868639 — intervention group
Group type: COMPARATOR
Intervention: Daily dosing (usual medication)
Number of subjects: 35
Study 19833743 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine
Number of subjects: 0
Study 16754827 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibullying school program
Number of subjects: 3816
Study 16754827 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3816
Study 15796091 — intervention group
Group type: EXPERIMENTAL
Intervention: PMBL treatment (sublingual tablet taken for ten consecutive days over three consecutive months)
Number of subjects: 89
Study 15796091 — intervention group
Group type: EXPERIMENTAL
Intervention: PMBL treatment
Number of subjects: 89
Study 15796091 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated children)
Number of subjects: 89
Study 15796091 — intervention group
Group type: EXPERIMENTAL
Intervention: Device for PMBL treatment
Number of subjects: 89
Study 11405516 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-treatment guidelines (group S)
Number of subjects: 245
Study 11405516 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 245
Study 9010904 — intervention group
Group type: EXPERIMENTAL
Intervention: Community education programs combined with low-cost mobile mammography van services for 2 years
Number of subjects: 0
Study 9010904 — intervention group
Group type: COMPARATOR
Intervention: Low-cost mobile mammography van services only
Number of subjects: 0
Study 7635647 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 21
Study 7635647 — intervention group
Group type: COMPARATOR
Intervention: Arteriography alone (Control)
Number of subjects: 21
Study 3582484 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline (0.25 mg)
Number of subjects: 8
Study 3582484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30785636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ego depletion
Number of subjects: 0
Study 29023624 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicled buccal fat pad with Emdogain (group I; n = 5)
Number of subjects: 10
Study 29023624 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicled buccal fat pad alone (group II; n = 5)
Number of subjects: 10
Study 26141306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathasept 4% locks
Number of subjects: 117
Study 26141306 — intervention group
Group type: COMPARATOR
Intervention: Heparin 5,000 U/mL locks
Number of subjects: 117
Study 22776860 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 262
Study 22776860 — intervention group
Group type: COMPARATOR
Intervention: Denosumab (after 4 years of placebo)
Number of subjects: 262
Study 22776860 — intervention group
Group type: COMPARATOR
Intervention: Placebo transitioning to Denosumab
Number of subjects: 262
Study 21610564 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferential hyperacuity perimetry (PHP)
Number of subjects: 200
Study 21610564 — intervention group
Group type: COMPARATOR
Intervention: No intervention (before use of PHP)
Number of subjects: 200
Study 19610504 — intervention group
Group type: EXPERIMENTAL
Intervention: Single layer continuous technique (group A, n=24)
Number of subjects: 50
Study 19610504 — intervention group
Group type: COMPARATOR
Intervention: Double layer continuous technique (group B, n=26)
Number of subjects: 50
Study 19610504 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall hospital mortality
Number of subjects: 50
Study 16273330 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (polyethylene glycol; Group 1)
Number of subjects: 50
Study 16273330 — intervention group
Group type: COMPARATOR
Intervention: No preparation (Group 2)
Number of subjects: 50
Study 12684804 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdiaphragmatic drain
Number of subjects: 70
Study 12684804 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drain)
Number of subjects: 70
Study 10632003 — intervention group
Group type: EXPERIMENTAL
Intervention: Air (group I)
Number of subjects: 40
Study 10632003 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% hydroxypropyl methylcellulose (HPMC) (group II)
Number of subjects: 40
Study 10632003 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced saline solution (BSS) (group III)
Number of subjects: 40
Study 10632003 — intervention group
Group type: COMPARATOR
Intervention: No adjunct (group IV)
Number of subjects: 40
Study 9110100 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day for six weeks
Number of subjects: 6
Study 9110100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8237626 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide by intravenous bolus
Number of subjects: 18
Study 8237626 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide orally
Number of subjects: 18
Study 8237626 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide (both intravenous and oral)
Number of subjects: 18
Study 8237626 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver volume measurement
Number of subjects: 18
Study 8237626 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-availability measurement
Number of subjects: 18
Study 8237626 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic parameters measurement
Number of subjects: 18
Study 4036848 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms Se/day as selenomethionine with methionine
Number of subjects: 50
Study 4036848 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms Se/day as sodium selenite with methionine
Number of subjects: 50
Study 4036848 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms Se/day as sodium selenite without methionine
Number of subjects: 50
Study 4036848 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms Se/day as selenomethionine without methionine
Number of subjects: 50
Study 4036848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 4036848 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (general)
Number of subjects: 50
Study 31919319 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG intrauterine perfusion group
Number of subjects: 140
Study 31919319 — intervention group
Group type: COMPARATOR
Intervention: Control group (G2 fluid)
Number of subjects: 140
Study 29614960 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair based exercise (CCBE) delivered once a week in day centres and community groups, and twice a week in care homes.
Number of subjects: 128
Study 29614960 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair based exercise (CCBE)
Number of subjects: 128
Study 29614960 — intervention group
Group type: COMPARATOR
Intervention: Group reminiscence
Number of subjects: 128
Study 29614960 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 128
Study 27622997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg
Number of subjects: 142
Study 27622997 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab 3 mg/kg plus placebo
Number of subjects: 142
Study 27622997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 142
Study 27622997 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab alone
Number of subjects: 142
Study 25009957 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency between high-amplitude sucking and presentation of maternal voice
Number of subjects: 24
Study 25009957 — intervention group
Group type: COMPARATOR
Intervention: Yoked control group
Number of subjects: 24
Study 22483371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballroom dance program (EG)
Number of subjects: 75
Study 22483371 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 75
Study 20682687 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin intervention
Number of subjects: 2994
Study 20682687 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 2994
Study 17335299 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase beta (Fabrazyme)
Number of subjects: 0
Study 16034448 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg QD (Treatment phase-1)
Number of subjects: 21
Study 16034448 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (Placebo phase)
Number of subjects: 21
Study 16034448 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg QD (Treatment phase-2)
Number of subjects: 21
Study 12047009 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antipsychotics (specifically augmentation of clozapine)
Number of subjects: 0
Study 12047009 — intervention group
Group type: COMPARATOR
Intervention: Clozapine (as a monotherapy)
Number of subjects: 0
Study 10413398 — intervention group
Group type: EXPERIMENTAL
Intervention: Technologically advanced assessment methods (audio, computer, video)
Number of subjects: 1952
Study 10413398 — intervention group
Group type: COMPARATOR
Intervention: Traditional assessment methods (written, face-to-face)
Number of subjects: 1952
Study 8680294 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized tracking program for resident-patient encounters
Number of subjects: 0
Study 2193265 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotic therapy (cephalexin 500 mg every 6 hours)
Number of subjects: 90
Study 2193265 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotic therapy (cephalothin 1 g every 6 hours)
Number of subjects: 90
Study 2193265 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (oral and IV)
Number of subjects: 90
Study 361000 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg every 8 hours when rectal temperature >= 38.5°C)
Number of subjects: 195
Study 361000 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbitone (3.5 +/- 1 mg/kg per day)
Number of subjects: 195
Study 31502032 — intervention group
Group type: EXPERIMENTAL
Intervention: HoLEP
Number of subjects: 116
Study 31502032 — intervention group
Group type: EXPERIMENTAL
Intervention: ThuLEP
Number of subjects: 116
Study 31551378 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and PA counselling group
Number of subjects: 450
Study 31551378 — intervention group
Group type: COMPARATOR
Intervention: Relaxation group (control)
Number of subjects: 450
Study 27327566 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU of supplementary vitamin E
Number of subjects: 99
Study 27327566 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 99
Study 27327566 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented group
Number of subjects: 99
Study 26330594 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation (n = 97)
Number of subjects: 189
Study 26330594 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (n = 92)
Number of subjects: 189
Study 23364373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine + Atropine (0.01 mg/kg)
Number of subjects: 200
Study 23364373 — intervention group
Group type: COMPARATOR
Intervention: Ketamine + Placebo (distilled water)
Number of subjects: 200
Study 23364373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine + Atropine
Number of subjects: 200
Study 23364373 — intervention group
Group type: COMPARATOR
Intervention: Ketamine + Placebo
Number of subjects: 200
Study 22193788 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly feedback to clinicians
Number of subjects: 340
Study 22193788 — intervention group
Group type: COMPARATOR
Intervention: Feedback every 90 days (control)
Number of subjects: 340
Study 19667976 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn) 1200 mg
Number of subjects: 95
Study 19667976 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn) 600 mg
Number of subjects: 95
Study 19667976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 17941782 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy (LDN)
Number of subjects: 40
Study 17941782 — intervention group
Group type: COMPARATOR
Intervention: Open donor nephrectomy (ODN)
Number of subjects: 40
Study 15234478 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection (acute pain)
Number of subjects: 12
Study 15234478 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic saline injection (fear of pain)
Number of subjects: 12
Study 15234478 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpredictable electric shocks (fear of impending pain)
Number of subjects: 12
Study 12812861 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD patients
Number of subjects: 23
Study 12812861 — intervention group
Group type: COMPARATOR
Intervention: Healthy comparison subjects
Number of subjects: 23
Study 12812861 — intervention group
Group type: COMPARATOR
Intervention: PTSD patients and controls
Number of subjects: 23
Study 11542706 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Body Negative Pressure (LBNP) group, subjected to -30 mm Hg for 1 hour per day during the last week of HDT.
Number of subjects: 12
Study 11542706 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) without LBNP.
Number of subjects: 12
Study 11542706 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LBNP and CON) during HDT.
Number of subjects: 12
Study 11542706 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after LBNP.
Number of subjects: 12
Study 7566020 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg each evening)
Number of subjects: 6595
Study 2190884 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (HD-CTX) with rhGM-CSF (5.5 micrograms/kg/day by continuous iv infusion for 14 days)
Number of subjects: 0
Study 2190884 — intervention group
Group type: COMPARATOR
Intervention: High-dose cyclophosphamide (HD-CTX) without rhGM-CSF
Number of subjects: 0
Study 2190884 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (HD-CTX) with rhGM-CSF
Number of subjects: 0
Study 474381 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK (30% glucose solution with 50 units of regular insulin and 80 mM KCl per liter, 50 mol. bolus followed by 1 ml./Kg./hr.)
Number of subjects: 9
Study 474381 — intervention group
Group type: COMPARATOR
Intervention: NSS (normal saline, 50 mol. bolus followed by 1 ml./Kg./hr.)
Number of subjects: 9
Study 474381 — intervention group
Group type: COMPARATOR
Intervention: Control (no infusion)
Number of subjects: 9
Study 31789800 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation (supervised exercise therapy) in addition to standard care (10 days of prednisolone, general information, and counseling)
Number of subjects: 65
Study 31789800 — intervention group
Group type: COMPARATOR
Intervention: Standard care (10 days of prednisolone, general information, and counseling)
Number of subjects: 65
Study 31596723 — intervention group
Group type: EXPERIMENTAL
Intervention: On-Pump CABG
Number of subjects: 60
Study 31596723 — intervention group
Group type: COMPARATOR
Intervention: Off-Pump CABG
Number of subjects: 60
Study 31596723 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (On-Pump and Off-Pump CABG)
Number of subjects: 60
Study 28804046 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic machine (Pn)
Number of subjects: 36
Study 28804046 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate-loaded machine (PL)
Number of subjects: 36
Study 25487899 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipped axilla
Number of subjects: 85
Study 25487899 — intervention group
Group type: COMPARATOR
Intervention: Unclipped axilla
Number of subjects: 85
Study 25487899 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate surgical preparation
Number of subjects: 85
Study 23521510 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency skin ultrasonography (Derma Scan Cortex Technology, version 3)
Number of subjects: 16
Study 21603893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (100 ng/ml blood plasma level)
Number of subjects: 0
Study 21603893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19358171 — intervention group
Group type: EXPERIMENTAL
Intervention: Defunctioning stoma
Number of subjects: 11429
Study 17394048 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral polyethylene glycol lavage solution and enemas (group A)
Number of subjects: 97
Study 17394048 — intervention group
Group type: COMPARATOR
Intervention: No preparation (group B)
Number of subjects: 97
Study 15338804 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild persistent asthma management
Number of subjects: 400
Study 15338804 — intervention group
Group type: COMPARATOR
Intervention: Daily symptoms
Number of subjects: 400
Study 15338804 — intervention group
Group type: COMPARATOR
Intervention: Medical intervention for asthma flares
Number of subjects: 400
Study 15338804 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma symptoms and beta-agonist use
Number of subjects: 400
Study 11705298 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 0
Study 11705298 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 0
Study 9555777 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral d-sotalol
Number of subjects: 3121
Study 9555777 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 3121
Study 7568678 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid etching (group 1)
Number of subjects: 60
Study 7568678 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% maleic acid etching (group 2)
Number of subjects: 60
Study 30995230 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria
Number of subjects: 817
Study 30995230 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningitis
Number of subjects: 817
Study 30995230 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis
Number of subjects: 817
Study 30995230 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptococcus pneumoniae infections
Number of subjects: 817
Study 30995230 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition
Number of subjects: 817
Study 30995230 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastro-enteritis / diarrhoea
Number of subjects: 817
Study 30995230 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaemia
Number of subjects: 817
Study 30995230 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV
Number of subjects: 817
Study 28168303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 mg/kg Q3W
Number of subjects: 101
Study 28168303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg Q3W
Number of subjects: 101
Study 28168303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg Q2W
Number of subjects: 101
Study 28168303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab in patients with PD-L1 TPS ≥50%
Number of subjects: 101
Study 28168303 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 101
Study 28168303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 101
Study 26177957 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal-mediated electrical stimulation
Number of subjects: 0
Study 26177957 — intervention group
Group type: COMPARATOR
Intervention: Implantation of DIAMOND device (placebo effect)
Number of subjects: 0
Study 23883162 — intervention group
Group type: EXPERIMENTAL
Intervention: Anma massage therapy (40-min session once weekly for 2 months, total of 8 sessions)
Number of subjects: 60
Study 23883162 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Anma massage sessions, followed by medical doctors)
Number of subjects: 60
Study 23883162 — intervention group
Group type: EXPERIMENTAL
Intervention: Anma massage therapy
Number of subjects: 60
Study 23883162 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 21910213 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 22
Study 21910213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 19637289 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (4 weeks of aerobic cycling exercise)
Number of subjects: 19
Study 16458680 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment (12 argon spots)
Number of subjects: 145
Study 15023378 — intervention group
Group type: EXPERIMENTAL
Intervention: 800mg chondroitin sulfate (CS) per day for two periods of 3 months during 1 year
Number of subjects: 120
Study 15023378 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 120
Study 15023378 — intervention group
Group type: EXPERIMENTAL
Intervention: 800mg chondroitin sulfate (CS)
Number of subjects: 120
Study 11182624 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy initiated within 24 hours after the onset of symptoms of an acute MI
Number of subjects: 0
Study 11182624 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin in patients with prior occlusive cardiovascular disease
Number of subjects: 0
Study 11182624 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin in primary prevention trials
Number of subjects: 0
Study 9270582 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad thoughts (self-induced sadness)
Number of subjects: 14
Study 9270582 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy thoughts (self-induced happiness)
Number of subjects: 14
Study 9270582 — intervention group
Group type: COMPARATOR
Intervention: Mental counting (control condition)
Number of subjects: 14
Study 8309674 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclins
Number of subjects: 12
Study 8309674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3711368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0